Cargando…

The Low Prevalence of Inclusion Body Myositis in an Outpatient Rheumatology Myositis Cohort

Introduction Sporadic inclusion body myositis (IBM) is a rare type of myopathy of unknown etiology typified by the presence of distinctive muscle fiber inclusions. IBM belongs to a larger family of conditions called the idiopathic inflammatory myopathies (IIM). This study seeks to compare the preval...

Descripción completa

Detalles Bibliográficos
Autores principales: Edigin, Ehizogie, Hassan, Ahmed S, Mathur, Tanisha, Manadan, Augustine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500712/
https://www.ncbi.nlm.nih.gov/pubmed/32963913
http://dx.doi.org/10.7759/cureus.9873
_version_ 1783583909531877376
author Edigin, Ehizogie
Hassan, Ahmed S
Mathur, Tanisha
Manadan, Augustine
author_facet Edigin, Ehizogie
Hassan, Ahmed S
Mathur, Tanisha
Manadan, Augustine
author_sort Edigin, Ehizogie
collection PubMed
description Introduction Sporadic inclusion body myositis (IBM) is a rare type of myopathy of unknown etiology typified by the presence of distinctive muscle fiber inclusions. IBM belongs to a larger family of conditions called the idiopathic inflammatory myopathies (IIM). This study seeks to compare the prevalence, clinical manifestations, and disease course of IBM patients to a cohort of polymyositis (PM) and dermatomyositis (DM) patients in an outpatient rheumatology myositis cohort. Methods We conducted a retrospective chart review of all adult patients attending rheumatology clinics at the Cook County Hospital from 2006 to 2011 with the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9) diagnoses of idiopathic inflammatory myopathies (IIM). Data collected included patient demographics, serial muscle strength testing, serial creatine kinase (CK), muscle biopsies, and immunosuppressive therapies received.  Results We identified 112 patients with IIM with the following breakdown: 66 - dermatomyositis, 42 - polymyositis, and four - IBM. These four patients represent the primary cohort. They had a mean age of 67 years (range 62-74), the mean follow-up period of 15 months (range 3-47), mean initial muscle strength in the weakest group of 3.75 (range 2-5, standard deviation [SD]=1.3), mean initial CK of 1,968 U/L (range 313-4,795, SD=1,970), mean final muscle strength in the weakest group of 3.75 (range 3-4, SD=0.5), mean final CK of 1,326 U/L (range 213-2,943, SD=1,200). Conclusions Our IBM patients had many features similar to other described IBM cohorts, including older age, male predominance, slow progression (stable CK and muscle strength), and lack of response to immunosuppressive therapy. Interestingly, we found a low prevalence of IBM in our outpatient rheumatology IIM cohort.
format Online
Article
Text
id pubmed-7500712
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-75007122020-09-21 The Low Prevalence of Inclusion Body Myositis in an Outpatient Rheumatology Myositis Cohort Edigin, Ehizogie Hassan, Ahmed S Mathur, Tanisha Manadan, Augustine Cureus Dermatology Introduction Sporadic inclusion body myositis (IBM) is a rare type of myopathy of unknown etiology typified by the presence of distinctive muscle fiber inclusions. IBM belongs to a larger family of conditions called the idiopathic inflammatory myopathies (IIM). This study seeks to compare the prevalence, clinical manifestations, and disease course of IBM patients to a cohort of polymyositis (PM) and dermatomyositis (DM) patients in an outpatient rheumatology myositis cohort. Methods We conducted a retrospective chart review of all adult patients attending rheumatology clinics at the Cook County Hospital from 2006 to 2011 with the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9) diagnoses of idiopathic inflammatory myopathies (IIM). Data collected included patient demographics, serial muscle strength testing, serial creatine kinase (CK), muscle biopsies, and immunosuppressive therapies received.  Results We identified 112 patients with IIM with the following breakdown: 66 - dermatomyositis, 42 - polymyositis, and four - IBM. These four patients represent the primary cohort. They had a mean age of 67 years (range 62-74), the mean follow-up period of 15 months (range 3-47), mean initial muscle strength in the weakest group of 3.75 (range 2-5, standard deviation [SD]=1.3), mean initial CK of 1,968 U/L (range 313-4,795, SD=1,970), mean final muscle strength in the weakest group of 3.75 (range 3-4, SD=0.5), mean final CK of 1,326 U/L (range 213-2,943, SD=1,200). Conclusions Our IBM patients had many features similar to other described IBM cohorts, including older age, male predominance, slow progression (stable CK and muscle strength), and lack of response to immunosuppressive therapy. Interestingly, we found a low prevalence of IBM in our outpatient rheumatology IIM cohort. Cureus 2020-08-19 /pmc/articles/PMC7500712/ /pubmed/32963913 http://dx.doi.org/10.7759/cureus.9873 Text en Copyright © 2020, Edigin et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Dermatology
Edigin, Ehizogie
Hassan, Ahmed S
Mathur, Tanisha
Manadan, Augustine
The Low Prevalence of Inclusion Body Myositis in an Outpatient Rheumatology Myositis Cohort
title The Low Prevalence of Inclusion Body Myositis in an Outpatient Rheumatology Myositis Cohort
title_full The Low Prevalence of Inclusion Body Myositis in an Outpatient Rheumatology Myositis Cohort
title_fullStr The Low Prevalence of Inclusion Body Myositis in an Outpatient Rheumatology Myositis Cohort
title_full_unstemmed The Low Prevalence of Inclusion Body Myositis in an Outpatient Rheumatology Myositis Cohort
title_short The Low Prevalence of Inclusion Body Myositis in an Outpatient Rheumatology Myositis Cohort
title_sort low prevalence of inclusion body myositis in an outpatient rheumatology myositis cohort
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500712/
https://www.ncbi.nlm.nih.gov/pubmed/32963913
http://dx.doi.org/10.7759/cureus.9873
work_keys_str_mv AT ediginehizogie thelowprevalenceofinclusionbodymyositisinanoutpatientrheumatologymyositiscohort
AT hassanahmeds thelowprevalenceofinclusionbodymyositisinanoutpatientrheumatologymyositiscohort
AT mathurtanisha thelowprevalenceofinclusionbodymyositisinanoutpatientrheumatologymyositiscohort
AT manadanaugustine thelowprevalenceofinclusionbodymyositisinanoutpatientrheumatologymyositiscohort
AT ediginehizogie lowprevalenceofinclusionbodymyositisinanoutpatientrheumatologymyositiscohort
AT hassanahmeds lowprevalenceofinclusionbodymyositisinanoutpatientrheumatologymyositiscohort
AT mathurtanisha lowprevalenceofinclusionbodymyositisinanoutpatientrheumatologymyositiscohort
AT manadanaugustine lowprevalenceofinclusionbodymyositisinanoutpatientrheumatologymyositiscohort